PRESS RELEASE published on 02/21/2024 at 14:15, 1 year 9 months ago Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024 Biotricity Inc. reports Q3FY24 financial results showing topline growth, increased subscription revenue, improved margins, lower costs, and a stronger path to breakeven in the remote cardiac monitor sector of consumer healthcare Healthcare Biotricity Inc. Q3FY24 Financial Results Subscription Revenue Remote Cardiac Monitor
BRIEF published on 02/21/2024 at 14:15, 1 year 9 months ago Biotricity Inc. announces growth with a significant increase in subscriptions for the third quarter of the 2024 fiscal year Financial Results Revenue Growth Biotricity Inc. Remote Cardiac Monitoring Technological Subscriptions
PRESS RELEASE published on 02/19/2024 at 14:00, 1 year 9 months ago Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st Biotricity Inc. to host Third Quarter FY 2024 Financial Results and Business Update Call on February 21, 2024, featuring Founder Dr. Waqaas Al-Siddiq and CFO John Ayanoglou. Event details and webcast information provided Financial Results Business Update Biotricity Inc. Investor Call Remote Health Monitoring
PRESS RELEASE published on 02/14/2024 at 14:00, 1 year 9 months ago Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024 Biotricity Inc. continues its shift to subscription-based revenue, emphasizing margin improvement and operational efficiency enhancements. Company to announce Third Quarter Fiscal 2024 Results on February 20, 2024 Operational Efficiency Biotricity Inc. Subscription-based Revenue Margin Improvement Third Quarter Fiscal 2024 Results
PRESS RELEASE published on 01/23/2024 at 14:15, 1 year 10 months ago Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats Biotricity Inc. (NASDAQ:BTCY) has announced the expansion of its Cardiac AI Cloud platform, aiming to develop predictive monitoring to identify issues before they occur, supporting earlier interventions, and reducing healthcare costs. The company's goal is to build comprehensive AI models for improved diagnoses and interventions, having analyzed over 360 billion heartbeats and helped diagnose over 200,000 patients. The development of large data models is crucial for supporting the intermittent nature of cardiac issues and the noisy data arising from ambulatory monitoring, and for helping cardiologists service more patients. The company's effort in building a comprehensive Cardiac AI Cloud platform aims to make cardiac care accessible, affordable, and scalable, thus providing necessary support and assistance to healthcare professionals. For more information, visit www.biotricity.com. Biotricity Inc. Cardiac AI Cloud Platform Predictive Monitoring Healthcare Costs Comprehensive AI Models
Published on 12/05/2025 at 02:35, 3 hours 30 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 5 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 5 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 34 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 14 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 39 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 50 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 54 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 5 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 20 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 21 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 4 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025